Olmesartán Hec (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Hec, is an angiotensin II receptor blocker presented as an oral dosage form for oral use. It treats hypertension in adult patients.

GNH USA supplies Olmesartán Hec as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan is an angiotensin II receptor blocker used to manage high blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events. - Essential hypertension: provides consistent blood pressure control when lifestyle measures are insufficient. - High‑risk hypertension: contributes to overall cardiovascular risk reduction in patients with additional risk factors.

Olmesartan is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: feeling light‑headed, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: general tiredness without exertion. - Nausea: occasional stomach upset. - Diarrhea: loose stools in some patients.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Hyperkalemia: elevated blood potassium levels that may cause cardiac arrhythmias. - Acute kidney injury: sudden decline in renal function, particularly in volume‑depleted patients. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hepatotoxicity: rare liver enzyme elevations or hepatitis.

Use of Olmesartan requires careful assessment of several safety factors.

- Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use with caution; liver function should be evaluated. - Hyperkalemia: avoid in patients with elevated serum potassium or those taking potassium‑sparing agents. - Concomitant aliskiren in diabetes: avoid combined use because of increased adverse renal outcomes. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several other medicines, influencing safety and efficacy.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can cause renal dysfunction and hyperkalemia. - ACE inhibitors or other ARBs: concurrent use raises risk of hypotension, hyperkalemia, and renal impairment. - Potassium‑sparing diuretics: may lead to dangerous elevations in serum potassium. - NSAIDs (e.g., ibuprofen, naproxen): can diminish antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, risking toxicity. - Thiazide diuretics: can enhance antihypertensive effect and affect electrolyte balance. - CYP450 inhibitors (e.g., ketoconazole): may modestly increase olmesartan plasma concentrations. - Antidiabetic drugs: blood glucose control may improve, requiring dose adjustments.